A Study of AGN-195263 for the Treatment of Meibomian Gland Dysfunction
NCT ID: NCT01633788
Last Updated: 2017-09-08
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
232 participants
INTERVENTIONAL
2012-08-22
2015-02-05
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Topical Ophthalmic AGN-195263 for the Treatment of Evaporative Dry Eye
NCT02965846
Topical Ophthalmic AGN-195263 for the Treatment of Evaporative Dry Eye
NCT02815293
Evaluation of AXR-270 for the Treatment of Posterior Blepharitis Associated With Meibomian Gland Dysfunction
NCT04469998
Characterization of Signs and Symptoms of Participants With and Without Meibomian Gland Dysfunction
NCT01979887
Safety, Tolerability and Systemic Pharmacokinetics of AGN-232411 in Healthy Participants and Participants With Dry Eye
NCT02420730
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
AGN-195263 0.1%
1 drop of AGN-195263 0.1% instilled in each eye twice daily.
AGN-195263 0.1%
1 drop of AGN-195263 0.1% instilled in each eye twice daily.
AGN-195263 0.03%
1 drop of AGN-195263 0.03% instilled in each eye twice daily.
AGN-195263 0.03%
1 drop of AGN-195263 0.03% instilled in each eye twice daily.
AGN-195263 0.01%
1 drop of AGN-195263 0.01% instilled in each eye twice daily.
AGN-195263 0.01%
1 drop of AGN-195263 0.01% instilled in each eye twice daily.
AGN-195263 Vehicle
1 drop of AGN-195263 vehicle (placebo) instilled in each eye twice daily.
AGN-195263 Vehicle
1 drop of AGN-195263 vehicle (placebo) instilled in each eye twice daily.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
AGN-195263 0.1%
1 drop of AGN-195263 0.1% instilled in each eye twice daily.
AGN-195263 0.03%
1 drop of AGN-195263 0.03% instilled in each eye twice daily.
AGN-195263 0.01%
1 drop of AGN-195263 0.01% instilled in each eye twice daily.
AGN-195263 Vehicle
1 drop of AGN-195263 vehicle (placebo) instilled in each eye twice daily.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Best-corrected visual acuity of 20/40 or better in each eye
Exclusion Criteria
* History of breast cancer
* Using LATISSE® or any other eye lash growth-stimulating product at least 30 days prior to the screening visit, or anticipated use during the study
* Contact lens wear in either eye during any portion of the study
* Unable to instill eye drops correctly
* History of corneal refractive surgery in either eye within 1 year
40 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Allergan
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Medical Director
Role: STUDY_DIRECTOR
Allergan
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Cornea Consultants of Arizona
Phoenix, Arizona, United States
University of Arkansas for Medical
Little Rock, Arkansas, United States
Sall Research Medical Center
Artesia, California, United States
Orange County Ophthalmology Medical Group, Inc.
Garden Grove, California, United States
Lugene Eye Institute
Glendale, California, United States
Lakeside Vision Center
Irvine, California, United States
Scripps Clinic
La Jolla, California, United States
North Valley Eye Medical Group, Inc.
Mission Hills, California, United States
Eye Research Foundation
Newport Beach, California, United States
North Bay Eye Associates, Inc.
Petaluma, California, United States
Centennial Eye Associates
Centennial, Colorado, United States
Colorado Eye Associates, PC
Colorado Springs, Colorado, United States
Danbury Eye Physicians & Surgeons, PC
Danbury, Connecticut, United States
The Eye Associates of Manatee, LLP
Bradenton, Florida, United States
Wohl Eye Center
Bloomingdale, Illinois, United States
John-Kenyon American Eye Institute
New Albany, Indiana, United States
Durrie Vision
Overland Park, Kansas, United States
Taustine Eye Center
Louisville, Kentucky, United States
Lifelong Vision Foundation
Chesterfield, Missouri, United States
Tauber Eye Center
Kansas City, Missouri, United States
Ophthalmology Associates
St Louis, Missouri, United States
Comprehensive Eye Care, Ltd.
Washington, Missouri, United States
Northern New Jersey Eye Institute, PA
South Orange, New Jersey, United States
Rochester Ophthalmological Group, PC
Rochester, New York, United States
Ophthalmic Consultants Long Island
Rockville Centre, New York, United States
South Shore Eye Care, LLP
Wantagh, New York, United States
Cornerstone Eye Care
High Point, North Carolina, United States
Drs. Fine, Hoffman, and Packer, LLC
Eugene, Oregon, United States
Vision Center of Texas, PA
Cedar Park, Texas, United States
University of Houston, College of Optometry
Houston, Texas, United States
Focus Clinical Research
Salt Lake City, Utah, United States
Stacy Smith, MD, PC
Salt Lake City, Utah, United States
Virginia Eye Consultants
Norfolk, Virginia, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
195263-006
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.